Analysis-Q1 results review: Elara Capital's call on Glenmark Pharma

Glenmark Pharma has reported a rise of 23.5% (YoY) in its first quarter net profit. In an interview with CNBC-TV18, Surajit Pal, pharma analyst, Elara Capital said, the top-line is very much in line, just 3% below his expectations. “Bottom-line margin